Increased levels of macrophage inflammatory proteins result in resistance to R5-tropic HIV-1 in a subset of elite controllers

Journal of Virology

Volumn 89, Issue 10, 2015, Pages 5502-5514

  Walker, Wendy E ^a,b   Kurscheid, Sebastian ^b   Joshi, Samit ^b   Lopez, Charlie A ^a   Goh, Gerald ^b   Choi, Murim ^b   Barakat, Lydia ^b   Francis, John ^b   Fisher, Ann ^b   Kozal, Michael ^b   Zapata, Heidi ^b   Shaw, Albert ^b   Lifton, Richard ^b,c   Sutton, Richard E ^b   Fikrig, Erol ^b,c  

^a Center of Excellence in Infectious Diseases Department of Biomedical Sciences TTUHSC El Paso   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; BETA CHEMOKINE; CCL3 PROTEIN, HUMAN; CCL3L1 PROTEIN, HUMAN; CCL4 PROTEIN, HUMAN; CCL5 PROTEIN, HUMAN; CCR5 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN; MACROPHAGE INFLAMMATORY PROTEIN; MESSENGER RNA;

ADULT; AGED; ARTICLE; CCL3 GENE; CCL3L1 GENE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION REGULATION; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MIDDLE AGED; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; UPREGULATION; VESICULOVIRUS; VIRAL TROPISM; VIRUS ENTRY; VIRUS LOAD; VIRUS RESISTANCE; VIRUS STRAIN; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; GENE DOSAGE; GENETICS; HIV SURVIVOR; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PATHOGENICITY; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; VESICULAR STOMATITIS VIRUS;

ADULT; AGED; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL3; CHEMOKINE CCL4; CHEMOKINE CCL5; CHEMOKINES, CC; COHORT STUDIES; FEMALE; GENE DOSAGE; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MACROPHAGE INFLAMMATORY PROTEINS; MALE; MIDDLE AGED; RECEPTORS, CCR5; RECEPTORS, CXCR4; RNA, MESSENGER; UP-REGULATION;

EID: 84928573402     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00118-15     Document Type: Article

References (61)

1. Deeks SG, Walker BD. 2007. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27:406-416. http://dx.doi.org/10.1016/j.immuni.2007.08.010.
2. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T, Petropoulos CJ, Rosenberg ES, Walker BD. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 197:563-571. http://dx.doi.org/10.1086/526786.
3. Riedel DJ, Sajadi MM, Armstrong CL, Cummings JS, Cairo C, Redfield RR, Pauza CD. 2009. Natural viral suppressors of HIV-1 have a unique capacity to maintain gammadelta T cells. AIDS 23:1955-1964. http://dx.doi.org/10.1097/QAD.0b013e32832ff1ff.
4. Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, Meyer L, Rouzioux C, Venet A, Delfraissy JF. 2005. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 41:1053-1056. http://dx.doi.org/10.1086/433188.
5. Miura T, Brockman MA, Brumme CJ, Brumme ZL, Carlson JM, Pereyra F, Trocha A, Addo MM, Block BL, Rothchild AC, Baker BM, Flynn T, Schneidewind A, Li B, Wang YE, Heckerman D, Allen TM, Walker BD. 2008. Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J Virol 82:8422-8430. http://dx.doi.org/10.1128/JVI.00535-08.
6. Munoz A, Kirby AJ, He YD, Margolick JB, Visscher BR, Rinaldo CR, Kaslow RA, Phair JP. 1995. Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+lymphocytes. J Acquir Immune Defic Syndr Hum Retrovirol 8:496-505. http://dx.doi.org/10.1097/00042560-199504120-00010.
7. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W. 1993. The characterization of non-progressors: long-term HIV-1 infection with stable CD4+T-cell levels. AIDS 7:1159-1166. http://dx.doi.org/10.1097/00002030-199309000-00002.
8. O'Brien TR, Blattner WA, Waters D, Eyster E, Hilgartner MW, Cohen AR, Luban N, Hatzakis A, Aledort LM, Rosenberg PS, Miley WJ, Kroner BL, Goedert JJ. 1996. Serum HIV-1RNAlevels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 276:105-110. http://dx.doi.org/10.1001/jama.1996.03540020027025.
9. Okulicz JF, Marconi VC, Landrum ML, Wegner S, Weintrob A, Ganesan A, Hale B, Crum-Cianflone N, Delmar J, Barthel V, Quinnan G, Agan BK, Dolan MJ. 2009. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis 200:1714-1723. http://dx.doi.org/10.1086/646609.
10. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Carrington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo MM, Allen TM, et al. 2010. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330:1551-1557. http://dx.doi.org/10.1126/science.1195271.
11. Blankson JN. 2010. Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? Antiviral Res 85:295-302. http://dx.doi.org/10.1016/j.antiviral.2009.08.007.
12. O'Connell KA, Bailey JR, Blankson JN. 2009. Elucidating the elite: mechanisms of control in HIV-1 infection. Trends Pharmacol Sci 30:631-637. http://dx.doi.org/10.1016/j.tips.2009.09.005.
13. Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, Martin JN, Nixon DF, McCune JM, Deeks SG. 2005. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 79:14169-14178. http://dx.doi.org/10.1128/JVI.79.22.14169-14178.2005.
14. Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, McCune JM, Deeks SG. 2008. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol 82:5398-5407. http://dx.doi.org/10.1128/JVI.02176-07.
15. Potter SJ, Lacabaratz C, Lambotte O, Perez-Patrigeon S, Vingert B, Sinet M, Colle JH, Urrutia A, Scott-Algara D, Boufassa F, Delfraissy JF, Theze J, Venet A, Chakrabarti LA. 2007. Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol 81:13904-13915. http://dx.doi.org/10.1128/JVI.01401-07.
16. Zaunders JJ, Ip S, Munier ML, Kaufmann DE, Suzuki K, Brereton C, Sasson SC, Seddiki N, Koelsch K, Landay A, Grey P, Finlayson R, Kaldor J, Rosenberg ES, Walker BD, Fazekas de St Groth B, Cooper DA, Kelleher AD. 2006. Infection of CD127+ (interleukin-7 receptor+) CD4+ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection. J Virol 80: 10162-10172. http://dx.doi.org/10.1128/JVI.00249-06.
17. Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, Palmer S, Brockman M, Rathod A, Piechocka-Trocha A, Baker B, Zhu B, Le Gall S, Waring MT, Ahern R, Moss K, Kelleher AD, Coffin JM, Freeman GJ, Rosenberg ES, Walker BD. 2007. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 8:1246-1254. http://dx.doi.org/10.1038/ni1515.
18. Graf EH, Mexas AM, Yu JJ, Shaheen F, Liszewski MK, Di Mascio M, Migueles SA, Connors M, O'Doherty U. 2011. Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog 7:e1001300. http://dx.doi.org/10.1371/journal.ppat.1001300.
19. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, Van Baarle D, Kostense S, Miedema F, McLaughlin M, Ehler L, Metcalf J, Liu S, Connors M. 2002. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 3:1061-1068. http://dx.doi.org/10.1038/ni845.
20. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107:4781-4789. http://dx.doi.org/10.1182/blood-2005-12-4818.
21. Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, Pantaleo G. 2005. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci USA 102:7239-7244. http://dx.doi.org/10.1073/pnas.0502393102.
22. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, Asher TE, Samri A, Schnuriger A, Theodorou I, Costagliola D, Rouzioux C, Agut H, Marcelin AG, Douek D, Autran B, Appay V. 2007. Superior control of HIV-1 replication by CD8+T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204:2473-2485. http://dx.doi.org/10.1084/jem.20070784.
23. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, Barre-Sinoussi F, Delfraissy JF, Sinet M, Pancino G, Venet A. 2007. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 104:6776-6781. http://dx.doi.org/10.1073/pnas.0611244104.
24. Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, Lai J, Gandhi SK, Siliciano JD, Williams TM, Siliciano RF. 2007. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 81:2508-2518. http://dx.doi.org/10.1128/JVI.02165-06.
25. Bailey JR, Lassen KG, Yang HC, Quinn TC, Ray SC, Blankson JN, Siliciano RF. 2006. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J Virol 80: 4758-4770. http://dx.doi.org/10.1128/JVI.80.10.4758-4770.2006.
26. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN. 2008. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol 82:3125-3130. http://dx.doi.org/10.1128/JVI.01533-07.
27. O'Connell KA, Han Y, Williams TM, Siliciano RF, Blankson JN. 2009. Role of natural killer cells in a cohort of elite suppressors: low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus type 1 replication in vitro. J Virol 83:5028-5034. http://dx.doi.org/10.1128/JVI.02551-08.
28. Saez-Cirion A, Shin SY, Versmisse P, Barre-Sinoussi F, Pancino G. 2010. Ex vivo T cell-based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responses. Nat Protoc 5:1033-1041. http://dx.doi.org/10.1038/nprot.2010.73.
29. Chen H, Li C, Huang J, Cung T, Seiss K, Beamon J, Carrington MF, Porter LC, Burke PS, Yang Y, Ryan BJ, Liu R, Weiss RH, Pereyra F, Cress WD, Brass AL, Rosenberg ES, Walker BD, Yu XG, Lichterfeld M. 2011. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest 121:1549-1560. http://dx.doi.org/10.1172/JCI44539.
30. Saez-Cirion A, Hamimi C, Bergamaschi A, David A, Versmisse P, Melard A, Boufassa F, Barre-Sinoussi F, Lambotte O, Rouzioux C, Pancino G. 2011. Restriction of HIV-1 replication in macrophages and CD4+T cells from HIV controllers. Blood 118:955-964. http://dx.doi.org/10.1182/blood-2010-12-327106.
31. Julg B, Pereyra F, Buzon MJ, Piechocka-Trocha A, Clark MJ, Baker BM, Lian J, Miura T, Martinez-Picado J, Addo MM, Walker BD. 2010. Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis 51:233-238. http://dx.doi.org/10.1086/653677.
32. Rabi SA, O'Connell KA, Nikolaeva D, Bailey JR, Jilek BL, Shen L, Page KR, Siliciano RF, Blankson JN. 2011. Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection. J Virol 85:979-986. http://dx.doi.org/10.1128/JVI.01721-10.
33. O'Connell KA, Rabi SA, Siliciano RF, Blankson JN. 2011. CD4+ T cells from elite suppressors are more susceptible to HIV-1 but produce fewer virions than cells from chronic progressors. Proc Natl Acad Sci U S A 108:E689-E698. http://dx.doi.org/10.1073/pnas.1108866108.
34. Buzon MJ, Seiss K, Weiss R, Brass AL, Rosenberg ES, Pereyra F, Yu XG, Lichterfeld M. 2011. Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers. J Virol 85:9646-9650. http://dx.doi.org/10.1128/JVI.05327-11.
35. Finkelshtein D, Werman A, Novick D, Barak S, Rubinstein M. 2013. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A 110:7306-7311. http://dx.doi.org/10.1073/pnas.1214441110.
36. Elinav H, Wu Y, Coskun A, Hryckiewicz K, Kemler I, Hu Y, Rogers H, Hao B, Ben Mamoun C, Poeschla E, Sutton R. 2012. Human CRM1 augments production of infectious human and feline immunodeficiency viruses from murine cells. J Virol 86:12053-12068. http://dx.doi.org/10.1128/JVI.01970-12.
37. Andrews S. 2012. FastQC-a quality control tool for high throughput sequence data. http://www.bioinformatics.babraham.ac.uk/projects/fastqc/.
38. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. 2013. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 14:R36. http://dx.doi.org/10.1186/gb-2013-14-4-r36.
39. Garber M, Grabherr MG, Guttman M, Trapnell C. 2011. Computational methods for transcriptome annotation and quantification using RNA-seq. Nat Methods 8:469-477. http://dx.doi.org/10.1038/nmeth.1613.
40. Goff L, Trapnell C, Kelley DR. 2012. cummeRbund: analysis, exploration, manipulation, and visualization of Cufflinks high-throughput sequencing data. Fred Hutchinson Cancer Research Center, Seattle, WA. http://bioconductor.org/.
41. Ruiz A, Royo JL, Rubio A, Borrego S, Leal M, Sanchez B, Nunez-Roldan A, Antinolo G. 2001. Spectrofluorimetric analysis of CCR5-delta 32 allele using real-time polymerase chain reaction: prevalence in southern Spanish HIV(+) patients and noninfected population. AIDS Res Hum Retroviruses 17:191-193. http://dx.doi.org/10.1089/08892220150217283.
42. Kalliolias GD, Ivashkiv LB. 2008. IL-27 activates human monocytes via STAT1 and suppresses IL-10 production but the inflammatory functions of IL-27 are abrogated by TLRs and p38. J Immunol 180:6325-6333. http://dx.doi.org/10.4049/jimmunol.180.9.6325.
43. Yang HN, Park JS, Woo DG, Jeon SY, Do HJ, Lim HY, Kim JH, Park KH. 2011. C/EBP-alpha and C/EBP-beta-mediated adipogenesis of human mesenchymal stem cells (hMSCs) using PLGA nanoparticles complexed with poly(ethyleneimmine). Biomaterials 32:5924-5933. http://dx.doi.org/10.1016/j.biomaterials.2011.04.072.
44. Nakamoto T, Yasuda K, Yasuhara M, Nakajima T, Mizokami T, Okada H, Kanzaki H. 2006. Cigarette smoke extract enhances oxytocin-induced rhythmic contractions of rat and human preterm myometrium. Reproduction 132:343-353. http://dx.doi.org/10.1530/rep.1.00908.
45. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, Nibbs RJ, Freedman BI, Quinones MP, Bamshad MJ, Murthy KK, Rovin BH, Bradley W, Clark RA, Anderson SA, O'Connell RJ, Agan BK, Ahuja SS, Bologna R, Sen L, Dolan MJ, Ahuja SK. 2005. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307:1434-1440. http://dx.doi.org/10.1126/science.1101160.
46. Townson JR, Barcellos LF, Nibbs RJ. 2002. Gene copy number regulates the production of the human chemokine CCL3-L1. Eur J Immunol 32: 3016-3026. http://dx.doi.org/10.1002/1521-4141(2002010)32:10<3016::AID-IMMU3016>3.0.CO;2-D.
47. Colobran R, Pedrosa E, Carretero-Iglesia L, Juan M. 2010. Copy number variation in chemokine superfamily: the complex scene of CCL3L-CCL4L genes in health and disease. Clin Exp Immunol 162:41-52. http://dx.doi.org/10.1111/j.1365-2249.2010.04224.x.
48. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD, Koup RA. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2:1240-1243. http://dx.doi.org/10.1038/nm1196-1240.
49. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. 1995. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270: 1811-1815. http://dx.doi.org/10.1126/science.270.5243.1811.
50. Saha K, Bentsman G, Chess L, Volsky DJ. 1998. Endogenous production of beta-chemokines by CD4+, but not CD8+, T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro. J Virol 72:876-881.
51. Cocchi F, DeVico AL, Yarchoan R, Redfield R, Cleghorn F, Blattner WA, Garzino-Demo A, Colombini-Hatch S, Margolis D, Gallo RC. 2000. Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci U S A 97:13812-13817. http://dx.doi.org/10.1073/pnas.240469997.
52. Kumar D, Parato K, Kumar A, Sun E, Cameron DW, Angel JB. 1999. Sustained suppression of plasma HIV RNA is associated with an increase in the production of mitogen-induced MIP-1alpha and MIP-1beta. AIDS Res Hum Retroviruses 15:1073-1077. http://dx.doi.org/10.1089/088922299310368.
53. Menten P, Wuyts A, Van Damme J. 2002. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 13:455-481. http://dx.doi.org/10.1016/S1359-6101(02)00045-X.
54. Aquaro S, Menten P, Struyf S, Proost P, Van Damme J, De Clercq E, Schols D. 2001. The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages. J Virol 75:4402-4406. http://dx.doi.org/10.1128/JVI.75.9.4402-4406.2001.
55. Hollox EJ, Hoh BP. 2014. Human gene copy number variation and infectious disease. Hum Genet 133:1217-1233. http://dx.doi.org/10.1007/s00439-014-1457-x.
56. Dolan MJ, Kulkarni H, Camargo JF, He W, Smith A, Anaya JM, Miura T, Hecht FM, Mamtani M, Pereyra F, Marconi V, Mangano A, Sen L, Bologna R, Clark RA, Anderson SA, Delmar J, O'Connell RJ, Lloyd A, Martin J, Ahuja SS, Agan BK, Walker BD, Deeks SG, Ahuja SK. 2007. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIVAIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol 8:1324-1336. http://dx.doi.org/10.1038/ni1521.
57. Kulkarni H, Agan BK, Marconi VC, O'Connell RJ, Camargo JF, He W, Delmar J, Phelps KR, Crawford G, Clark RA, Dolan MJ, Ahuja SK. 2008. CCL3L1-CCR5 genotype improves the assessment of AIDS risk in HIV-1-infected individuals. PLoS One 3:e3165. http://dx.doi.org/10.1371/journal.pone.0003165.
58. Ahuja SK, Kulkarni H, Catano G, Agan BK, Camargo JF, He W, O'Connell RJ, Marconi VC, Delmar J, Eron J, Clark RA, Frost S, Martin J, Ahuja SS, Deeks SG, Little S, Richman D, Hecht FM, Dolan MJ. 2008. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med 14:413-420. http://dx.doi.org/10.1038/nm1741.
59. Shao W, Tang J, Song W, Wang C, Li Y, Wilson CM, Kaslow RA. 2007. CCL3L1 and CCL4L1: variable gene copy number in adolescents with and without human immunodeficiency virus type 1 (HIV-1) infection. Genes Immun 8:224-231. http://dx.doi.org/10.1038/sj.gene.6364378.
60. Urban TJ, Weintrob AC, Fellay J, Colombo S, Shianna KV, Gumbs C, Rotger M, Pelak K, Dang KK, Detels R, Martinson JJ, O'Brien SJ, Letvin NL, McMichael AJ, Haynes BF, Carrington M, Telenti A, Michael NL, Goldstein DB. 2009. CCL3L1 and HIV/AIDS susceptibility. Nat Med 15:1110-1112. http://dx.doi.org/10.1038/nm1009-1110.
61. Bhattacharya T, Stanton J, Kim EY, Kunstman KJ, Phair JP, Jacobson LP, Wolinsky SM. 2009. CCL3L1 and HIV/AIDS susceptibility. Nat Med 15:1112-1115. http://dx.doi.org/10.1038/nm1009-1112.